Home Tags DS-8201a

Tag: DS-8201a

Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...

About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...

2017 San Antonio Breast Cancer Symposium will Highlight Several Antibody-Drug Conjugates...

This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad...

Pivotal Phase II Study of DS-8201 in Patients with HER2-Positive Metastatic...

Researchers at Daichi Sankyo initiation the DESTINY-Breast01, a pivotal phase II study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody-drug conjugate...

Phase I Study Shows Daichi Sankyo’s Anti-HER2 Antibody-drug Conjugate DS-8201a to...

Safety and preliminary efficacy data from a phase I study of DS-8201a (Daiichi Sankyo Company), a novel investigational HER2-targeting antibody drug conjugate or ADC,...